The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 17, 2024

Filed:

Dec. 23, 2020
Applicant:

Obi Pharma, Inc., Taipei, TW;

Inventors:

Michael Nientse Chang, Taipei, TW;

Jiann-Shiun Lai, Taipei, TW;

Wan-Fen Li, Taipei, TW;

I-Ju Chen, Taipei, TW;

Yi-Chien Tsai, Taipei, TW;

Kai-Chuan Chen, Taipei, TW;

Assignee:

OBI Pharma, Inc., Taipei, TW;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 49/00 (2006.01); A61K 49/16 (2006.01); A61K 51/10 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07K 16/18 (2006.01); C07K 16/30 (2006.01); C07K 16/44 (2006.01); C08B 37/00 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6855 (2017.08); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6811 (2017.08); A61K 47/6817 (2017.08); A61K 47/6843 (2017.08); A61K 47/6857 (2017.08); A61K 47/6859 (2017.08); A61K 47/6863 (2017.08); A61K 49/0058 (2013.01); A61K 49/16 (2013.01); A61K 51/1018 (2013.01); A61K 51/1051 (2013.01); A61K 51/1054 (2013.01); A61K 51/1057 (2013.01); A61K 51/1063 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 16/18 (2013.01); C07K 16/3076 (2013.01); C07K 16/44 (2013.01); C08B 37/0006 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01);
Abstract

Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.


Find Patent Forward Citations

Loading…